Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
As per available reports about 01 through its relevant journals, 41 Conferences, 02 workshops are presently dedicated exclusively to antiviral therapy and about 08 articles are being published on antiviral therapy.
Combination antiviral therapy helps prevent the virus that causes hepatitis C from reproducing in the body. Peginterferon and ribavirin often are combined for treatment. A protease inhibitor or a nucleotide analog inhibitor may be given along with peginterferon and ribavirin or with ribavirin alone. But some newer treatments do not use peginterferon or ribavirin.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance :
Combination antiviral therapy is prescribed for people who have ongoing (chronic) hepatitis C infection. It may be given to people who have never had treatment or when the first set of medicines has failed to cure the infection. The length of your treatment depends on what hepatitis C genotype you have. Genotypes 1 and 2 generally are treated for 12 weeks, and genotype 3 generally is treated for 12 or 24 weeks. If your viral load does not improve after initial treatment, a different set of medicines may be used.
Antiviral agents which are useful to restrict, a number of clinical situations. Furthermore, most antiviral drugs do not selectively inhibit virus replication without simultaneously injuring the host cell, and are therefore accompanied by serious side effects. Thus, possible beneficial effects of antiviral drugs must be balanced against potential immune-suppressive and other undesirable side effects. Nevertheless, the physician, faced with a seriously ill patient or concerned about the individual and economic consequences of an incipient epidemic of viral disease, is under considerable pressure by the patient, by the public or by his colleagues, to apply antiviral therapy. Although the pharmacology and use of antiviral drugs has been introduced for an overall reassessment of antiviral therapy, considering older approaches, such as post-exposure immunization, along with the newer chemotherapy, is lacking. Virus structure: Viruses contain a single type of nucleic acid, either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). The viral core, composed of the nucleic acid and nucleoproteins is protected by an outer protein coat (the capsid). Jr addition, some virus. arc surrounded by a lipoprotein envelope. Virus cell interactions: Virus are obligate intracellular parasites. The field of antiviral therapy is expanding at an unprecedented rate. The tremendous expansion in drug screening and rational drug design brought about by the HIV pandemic, together with gathering interest in new viral targets' such as the hepatitis and papillomaviruses, means that more antiviral agents than ever are reaching clinical trials.
In data for the antivirals therapeutics market from 2002 to 2010 with forecasts 2010 to 2017the global antivirals market was estimated to be worth $22.1 billion and is expected to reach revenues of approximately $30.1 billion by 2017 at a CAGR of 4.5% between 2010 and 2017. Overall antiviral market is driven by Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for 61% of the market 2010. Data and analysis on HIV, Hepatitis, Herpes and Influenza therapeutics market in the leading geographies of the world
International symposium and workshops:
Relevant Society and Associations:
This page will be updated regularly.
This page was last updated on 14th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising